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Kidney injury caused by immunoglobulin free light chains
(FLCs) in the setting of plasma cell dyscrasias is common
and associated with increased morbidity and mortality.
All compartments of the kidney may be affected, from the
glomerulus to the tubulointerstitium, in a wide variety of
disease patterns. Here, we review our current knowledge
of the biological effects of FLCs and the mechanisms that
lead to kidney injury.
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Plasma cell dyscrasias (PCD) are characterized by the
proliferation of a clone of B-cell lineage. There is associated
production of monoclonal immunoglobulin (Ig), which
frequently includes a variable quantity of monoclonal free
light chain (FLC). Each FLC clone has distinct physicochem-
ical properties, which in some circumstances cause tissue
injury. As FLCs are primarily cleared from the circulation by
the kidneys, this organ is often damaged in PCD.1–3 The
clinical features of this damage are wide, ranging from slowly
progressive chronic kidney disease, often associated with
heavy proteinuria, to life-threatening acute kidney injury.
Irreversible interstitial fibrosis can develop rapidly.4 In
multiple myeloma alone, up to 50% of patients have renal
impairment at diagnosis, 20% may have acute kidney injury,
and up to 10% require dialysis.5–8
Monoclonal FLCs can damage both the glomerular and
tubulointerstitial compartments in disease-dependent pat-
terns.9 For example, primary (AL) amyloidosis can affect all
compartments of the kidney, but predominantly involves the
glomeruli; in myeloma cast nephropathy, there is proximal
tubular inflammation and in the distal tubules, precipitation
of light chain casts with secondary interstitial involvement;
and light chain deposition disease (LCDD) can affect the
mesangium, the glomerular and tubular basement membranes,
and blood vessels. The clinical and histological features of
the different disease states are summarized in Table 1.
In this review, we link current understanding of the
biology of FLCs with the patterns of injury that develop in
the kidney. We describe how the structure of FLCs facilitates
pathological effects that are dependent on both the extra-
cellular deposition of proteins and the activation of
intracellular signaling pathways to produce distinct patterns
of injury.
LIGHT CHAIN STRUCTURE, PRODUCTION, AND DISTRIBUTION
An Ig molecule consists of two heavy chains and two light
chains, linked in a Y-shaped configuration.10,11 There are two
light chain isotypes (k and l), each containing a variable and
a constant region. The variable region of each light chain and
heavy chain pair constitutes the antigen-binding sites.
Each light chain contains around 220 amino acids (AAs)
and has a molecular weight of 25 kDa.12 Genes coding for
k- and l-light chains are situated on chromosomes 2 and 22,
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Table 1 | Renal manifestations of plasma cell dyscrasias, site and composition of deposits, and summary of clinical and
histological features
Renal
manifestation
Associated monoclonal
gammopathies
Sites of
deposits
Composition
of deposits Clinical features Histological features
Cast nephropathy
(myeloma kidney)
Multiple myeloma,
plasma cell leukemia,
and Waldenstro¨m’s
macroglobulinemia
PTEC, interstitium,
and distal tubules
LC+uromodulin Renal impairment
in nearly all cases.
In dialysis-dependent
ARF, independent
renal function regained
in o25%
PTEC damage, interstitial
inflammation, and fibrosis.
Distal tubular casts with
giant cell reaction. Found
in up to 70% of cases of
dialysis-dependent ARF
Amyloidosis AL amyloidosis,
AH amyloidosis,
multiple myeloma,
plasma cell leukemia,
and Waldenstro¨m’s
macroglobulinemia
All compartments
of kidney may
be affected,
but glomeruli
predominate
LC: k/l 1:3
HC
Renal impairment:
20% of patients at
diagnosis and ESRF
in 20% by 1 year
Proteinuria common
Deposits stain with Congo
red giving apple green
birefringence under
polarized light. EM:
fibrils 7–12 nm wide
and 30–1000nm long
Monoclonal
Ig deposition
diseases
(i) LCDD
(ii) HCDD
(iii) LHCDD
Multiple myeloma and
plasma cell leukemia
Mesangium,
peritubular areas,
vascular, and GBM
(i) LC: mainly
VkI and VkIV
(ii) HC
(iii) LC+HC (B10%
of LCDD cases)
Renal impairment:
96% of patients over
course of illness. ESRF
in 60% at 1 year.
Proteinuria 41 g/day:
84%. Nephrotic range
proteinuria: 40%
Prominent mesangial
nodules and
thickening of peripheral
basement membrane
IF: LC (also HC in HCDD
and LHCDD) in mesangial
nodules, peritubular
regions, vessels,
interstitium, and GBM.
EM: Fine granular deposits
Light chain
Fanconi syndrome
Multiple myeloma
and Waldenstro¨m’s
macroglobulinemia
Lysosomes in PTEC k/l 9:1 Acquired Fanconi
syndrome, type II
RTA, and chronic
renal impairment
Tubular atrophy and
interstitial fibrosis,
crystals concentrated
in PTEC lysosomes
Cryoglobulinemic
GN
Multiple myeloma
and plasma
cell leukemia
Glomeruli IgG-k or -l
IgM-k and
polyclonal IgG
Renal disease: 20% of
patients at diagnosis
and 450% during
course of illness.
Proteinuria and
microscopic hematuria
(30%), nephrotic
syndrome (20%),
CRF (20%), ARF (10%),
and ESRF in 15%
Thickened GBM, capillary
thrombi containing
precipitated cryoglobulins.
IF: diffuse glomerular
intracapillary IgM deposits
EM: subendothelial
fibrillar deposits
Waldenstro¨m’s
macroglobulinemia
glomerulonephritis
Waldenstro¨m’s
macroglobulinemia
Glomeruli IgM-k or -l,
LC
Renal involvement rare.
Nephrotic syndrome
and ARF can occur
(the latter due to
hyaline thrombi)
Nodular glomerulosclerosis
may be seen. Most patients
have interstitial infiltrates.
IF: IgM deposits within
capillary lumina
Immunotactoid
glomerulopathy
(including
GOMMID)
Plasma cell dyscrasia
only found in minority
of patients. Commonly
associated with
lymphoproliferative
diseases
Glomeruli IgG-k or -l Renal impairment,
nephrotic syndrome,
and hypertension
Membranous nephropathy
or membranoproliferative GN.
Congo red-negative organized
glomerular deposits.
EM: subendothelial-mixed
granular and organized
deposits with microtubular
(10–60 nm diameter)
organization
Proliferative GN
with monoclonal
Ig deposits
Serum monoclonal
Ig detected in 50%
of patients
Glomeruli Monoclonal
IgG-k or -l
Proteinuria present in all,
nephrotic syndrome in 44%.
Renal failure seen in 80%
Endocapillary proliferative or
membranoproliferative GN.
IF: monoclonal IgG.
EM: mesangial and
subendothelial granular deposits
Abbreviations: ARF, acute renal failure; CRF, chronic renal failure; EM, electron microscopy; ESRF, end-stage renal failure; GBM, glomerular basement membrane;
GN, glomerulonephritis; GOMMID, glomerulonephritis with organized microtubular monoclonal immunoglobulin deposit; HC, heavy chain; HCDD, heavy chain deposition
disease; IF, immunofluorescence; Ig, immunoglobulin; LC, light chain; LCDD, light chain deposition disease; LHCDD, light and heavy chain deposition disease; PTEC, proximal
tubule epithelial cell; RTA, renal tubular acidosis.
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respectively.13–15 There is little variation within the constant
(CL) regions of k- and l-light chains.
15,16 In contrast, the
variable (VL) region of a light chain comprises four
framework regions that form a hydrophobic core,17–21 within
which are scattered three hypervariable sequences called
complementary-determining regions (CDR1, CDR2, and
CDR3).17–19 The diversity of CDRs reflects the large number
of possible combinations of VL and joining (J) gene
segments, which encode them. The k-light chain is
constructed from 40 Vk and 5 Jk segments, and the l-light
chain from 30 Vl and 8 Jl segments, respectively,15 with AA
substitutions in the VL region resulting in structural
changes.22–25 Structural variations due to disparities and
mutations in gene segment combinations may determine the
toxicity of an individual FLC.
The presence of the amphipathic AAs tyrosine and
tryptophan in light chain CDRs may enable Ig to cross-react
with structurally similar ligands.26 These AAs: (i) are
unaffected by the change from a hydrophilic to a hydro-
phobic environment that occurs on antigen binding; (ii) take
part in electrostatic interactions; and (iii) have flexible side
chains that can generate a structurally plastic region.
Although these factors may improve antigen binding and
increase antibody efficacy, they may also predispose to
potential undesirable effects.
Normally, there is a 40% overproduction of light chain
compared with heavy chain.27 Around 500 mg/day of these
polyclonal FLCs are released into the circulation.28,29 On
proliferation of an aberrant clone of B-cell lineage, there may
be additional secretion of clonal FLC.
The k-FLCs are monomeric and the l-FLCs dimeric,
although higher oligomeric and polymeric forms of both
FLCs occur.27,30,31 FLCs rapidly disperse and are present in
roughly equal concentrations throughout extracellular com-
partments; almost 80% of FLC is extravascular.32 Two-thirds
of light chain production is k and this is reflected in a serum
k/l ratio of 1.8:1.33
RENAL HANDLING OF FLCs
FLCs are primarily removed by catabolism in proximal
tubular epithelial cells (PTECs).2,34,35 The precise glomerular
clearance is unknown, but figures for k-FLC of 40% per hour
and l-FLC of 20% per hour can be derived from size and
cationic charge,3,36 equating in normal kidney function to
serum half-lives of 2–4 h and 3–6 h, respectively.2,35 Conse-
quently, the serum ratio of FLC isotypes in normal renal
function is not a true representation of production, but a
function of differential clearance, with a k/l FLC ratio of
0.26–1.65 across all age groups.33 In severe renal failure, the
reticuloendothelial system becomes the main route of removal
and the serum half-life of FLCs increases to 32 h or more.34
As there is avid uptake and catabolism of FLCs by PTECs,37,38
only 1–10 mg/day of FLC is present in urine in normal kidney
function.2,3,39 If the FLC load exceeds the reabsorptive capacity
of PTECs, then significant amounts of FLC will pass into the
distal nephron and urinary levels will increase.
The internalization of FLCs by PTECs is a constant
process, not influenced by the isoelectric point (pI).40 Uptake
occurs through rapid and saturable megalin–cubilin receptor-
mediated endocytosis in clathrin-coated pits, resulting in
vesicular trafficking, where receptors return to the cell surface
and the endocytic vesicles containing their cargo enter the
endosomal–lysosomal pathway and are acidified.41–44 This
pathway is dependent on receptor-associated protein, which
has a chaperone-like function to megalin.45 Megalin and
cubilin bind a wide range of ligands, including albumin, and
provide a highly efficient physiological mechanism for
conserving AAs and essential protein-bound molecules.46–48
POLYCLONAL ELEVATIONS IN FLC LEVELS
Polyclonal elevations in FLCs may result from either reduced
clearance or increased production. As FLC clearance is
glomerular filtration dependent, serum FLCs increase as
kidney function declines.49 The levels are also elevated
(independent of renal function) with generalized B-cell
stimulation in conditions such as autoimmune diseases and
chronic infections.50,51
In vitro studies have indicated an immunomodulatory
potential of polyclonal FLCs on neutrophil function.52–54
However, there are no published studies to date on a direct
renal effect, and no demonstrable causative link between
polyclonal FLCs and kidney disease progression.
WHY DO SOME CLONAL FLCs CAUSE KIDNEY INJURY?
FLCs isolated from patients with PCD and kidney injury have
a greater potential to self-associate and form higher
molecular weight aggregates under physiological conditions
than FLCs from patients with PCD but without kidney
injury. This is irrespective of the underlying type of renal
injury.31 Furthermore, mice injected with FLCs from patients
with renal lesions developed similar lesions to the patients,
indicating that specific clones of FLCs cause distinct,
transferrable patterns of injury.55 This supports the principle
that the primary structure of the molecule is an important
determinant of the pattern of injury seen.
RESIDENT RENAL CELLS ARE DIFFERENTIALLY PREDISPOSED
TO INJURY BY FLCs
Glomerular-filtered FLCs are transported into the mesangium
or pass into tubular ultrafiltrate. The responses of mesangial and
tubular epithelial cells to the individual clone of FLC determine
the specific patterns of injury that are seen at both sites.
Mesangial cells (MCs) support and maintain the glomer-
ulus by secreting both extracellular matrix (ECM) and
mediators and enzymes such as matrix metalloproteinases
(MMPs), which regulate glomerular biology.56–63 Clonal FLC
may disrupt these processes and cause glomerular injury by:
(i) promoting phenotypic changes in MCs, (ii) secretion into
the ECM by MCs as amyloid fibrils or LCDD deposits; and
(iii) direct deposition into the mesangium without cell
processing. Figure 1 summarizes interactions of MCs with
glomerulopathic FLCs.
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DISEASE SPECIFIC CONSIDERATIONS FOR MCs AND
GLOMERULAR PATHOLOGY
AL amyloidosis
AL amyloidosis is defined in situ by immunostaining and
electron microscopy. The presence of hypervariable regions
may account for variable detection by antibodies in
conventional immunohistochemistry. Gold immunoelectron
microscopy is a more sensitive and reliable method for
identifying AL amyloidosis in situ;64 however, this is not
always available in routine clinical practice.65 Biochemical
typing of amyloid from formalin-fixed, paraffin-embedded
specimens, as well as proteomic techniques, have been
reported, but these are not widely available.66,67
In AL amyloidosis, FLCs aggregate into fibrillary, non-
branching, b-pleated sheet structures between 7 and 12 nm
thick. There is then progressive replacement of normal matrix
by amyloid fibrils, leading to destruction of glomerular
architecture.68–70 Intact FLCs and FLC fragments obtained
from plasma cells from patients with AL amyloidosis can also
be extracted from amyloid deposits in the kidneys of the
same patients, suggesting that abnormal synthesis and/or
ineffective proteolysis are important for disease develop-
ment.71 The role of abnormal synthesis is also supported
by the ability of human amyloidogenic FLCs to cause
amyloidosis in mice.72 A crucial cofactor in the develop-
ment of the disease is the presence of serum amyloid protein,
manufactured in the liver, which binds to and protects fibrils
from proteolytic degradation.73,74
Light chain variants and amyloidosis
AL amyloidosis is more frequently associated with l-FLCs
than k-FLCs.75–77 FLCs containing the VlVI subgroup are
differentially deposited in the glomerulus compared with
other sites,78,79 and the structural heterogeneity of the VL
region determines the organ specificity of the individual
FLC.22,23,75,76 Two recombinant VL domains derived from
amyloidogenic FLCs were less stable in thermodynamic
studies and tended to form fibrils compared with a VL
domain derived from non-amyloidogenic FLC,80 with
destabilizing AA substitutions inducing fibril formation,
FLC Putative LC
receptor
EndosomeLysosome
c-fos
NF-κB
c-fos
NF-κB
Transcription
Fibrillar
amyloid
deposits
↑ ECM
↑↑ PDGF-β
Macrophage
phenotype
↑ PDGF-β
LCDDAL amyloid
↑ TGF-β
↑ MCP-1 ↑ MCP-1
Granular
LCDD
deposits
with↑ECM
↑MMP
↓ECM
↓MMP
Myofibroblast
phenotype
Proliferation (early)
Surface ruffling
↓Tenascin
Inflammatory
cell infiltration
↑ CD68
↑ Cathepsin D
↓ SMA
↑ Mature
lysosomes
Apoptosis +
cell deletion (late)
↑ Tenascin
Inflammatory
cell infiltration
Proliferation (early)
Surface ruffling
↑Tenascin
↑ RER cisternae
↑ Golgi stacks
↑ EEA
↑ SMA
Figure 1 | Interactions of FLCs with mesangial cells (MCs): AL amyloidosis (left) and light chain deposition disease (LCDD; right).
Both AL amyloid and LCDD free light chains (FLCs) share a common route of entry into MCs via a putative receptor. However, they are
channeled into different intracellular-trafficking pathways and exhibit different effects on the cell. AL amyloid FLCs are catabolized within
lysosomes, whereas LCDD FLCs are processed in endosomes. Processed FLCs are deposited in the mesangium as fibrils in the case of AL
amyloidosis, or as granular deposits with increased extracellular matrix (ECM) in the case of LCDD. Both types of FLCs initiate intracellular
signaling, with migration of c-fos and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) to the nucleus, resulting in
transcription of monocyte chemotactic protein (MCP)-1 and platelet-derived growth factor (PDGF)-b. The release of PDGF-b is more
pronounced with LCDD FLCs compared with AL amyloid FLCs. MCP-1 recruits inflammatory cells. PDGF-b (i) causes cell surface ruffling,
resulting in increased cell surface area and (ii) promotes early MC proliferation, which is more pronounced in LCDD than AL amyloidosis.
Transforming growth factor (TGF)-b production is increased in LCDD, which (i) causes cell deletion later in the disease and (ii) increases
production of ECM proteins. Expression of matrix metalloproteinase (MMP)-7, which degrades tenascin, is reduced in LCDD. The result is
increased ECM. In AL amyloidosis, production of TGF-b is not increased and there is increased expression of MMPs, resulting in destruction
of ECM, which is then replaced by amyloid fibrils. In vitro, MCs undergo phenotypic changes in response to these FLCs: AL amyloid FLCs
induce a macrophage-like phenotype, in keeping with a more catabolic role. LCDD FLCs induce a myofibroblast-like phenotype, in keeping
with a more synthetic role. EEA, early endosomal antigen; LC, light chain; RER, rough endoplasmic reticulum; SMA, smooth muscle actin.
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further indicating that FLC instability may determine
amyloidogenic properties. Indeed, sequencing of AL amyloid
fibrils showed that constituent FLCs can have different
primary structures from AA substitutions.81,82
Changes in AA sequences may also lead to different
posttranslational modifications, such as glycosylation,22–25
which strongly correlate with formation of amyloid.22,83
Amyloidogenic FLCs may have abnormal glycosylation in the
CDR or framework regions.83 Introduction of glycosylation
receptor sites by AA substitutions may also increase the risk
of fibril formation.84
Differential tissue distribution in amyloid
In some groups of patients, despite amyloidogenic FLCs
being derived from the same gene with subsequent
similarities in FLC structure, there is variability in deposition
patterns.85 These observations imply that factors such as
somatic mutations and posttranslational modifications are
also important determinants of distribution. Additionally,
local tissue characteristics at deposition sites may be
important. This is supported by a case series of eight patients
with cardiac Ig deposition disease, in which four patients
showed amyloid deposition at extracardiac sites, but no
patients showed cardiac amyloid.86 The glomerular basement
membrane contains glycosaminoglycans, which can interact
with amyloidogenic proteins and promote fibril deposition
by: (i) inducing conformational changes; (ii) stabilizing these
proteins; and (iii) providing protection from proteolysis.87–91
LCDD
In LCDD, involvement of the tubular basement membrane is
most commonly present, although glomerular involvement
can also be seen. The k-FLCs, particularly those containing
the VkIV subgroup, are overrepresented.92,93 In patients with
PCD, LCDD is present in 5%,94 and two-thirds of these have
multiple myeloma.95 The classical light microscopy appearance
is of a nodular glomerulosclerosis.96 In early involvement, the
findings may resemble mesangial or membranoproliferative
glomerulonephritis.9,97 The nodules consist of ECM proteins
and clonal FLC. FLCs can also be deposited in glomerular
capillary walls.
There are unusual hydrophobic AA substitutions in the
CDR regions of LCDD-associated FLCs.98 These may
facilitate a one-step precipitation out of solution in tissues,
explaining the amorphous nature of LCDD deposits, as
opposed to the organized fibrils seen in amyloid, where
electrostatic interactions may be more important.
CELL-SPECIFIC PROCESSING AND ACTIVATION LEADS TO THE
DIFFERENTIAL PATTERNS THAT ARE SEEN IN FLC DISEASE
A direct toxic effect of FLCs on resident renal cells including
MCs is supported by the observation that chemotherapy,
targeting the plasma cell clone, can result in the rapid
improvement of clinical features such as proteinuria.99,100
These occur too early to be explained purely by regression of
disease in situ.101–103
Light chains affect MC function with expansion of
ECM,9,69,97,104–106 transformation of MC phenotype,104,107–111
and the deposition of FLC-derived protein in the mesan-
gium.69,97 However, there are fundamental differences
between disease states. For example, amyloidogenic FLCs in
vitro promote the transformation of MCs to a macrophage
phenotype.111 The cells develop lysosomes within which
degradation and remodeling of FLCs into amyloid oc-
cur.112–114 Conversely, MCs treated with LCDD FLCs are
more likely to evolve a myofibroblast phenotype.
Receptor-mediated uptake of FLCs by MCs has been
proposed.115,116 Although the receptor may be common,
different types of FLCs activate different signaling path-
ways.115,116 Amyloidogenic FLCs are internalized and trans-
ported to mature lysosomes, indicating involvement of the
clathrin-coated pit pathway. In contrast, LCDD FLCs are
predominantly phagocytosed into the endosomal compart-
ment. Preferential uptake of certain species of FLCs by MCs
may partly explain the preferential deposition in the kidney
of FLCs derived from specific germ lines such as
VlVI.79,111,116 Furthermore, tubulopathic FLCs are not taken
up into MCs, indicating no receptor uptake; in vivo they
would then enter the proximal tubule unhindered.115
Although MCs are necessary for the formation of amyloid,
there is both in vitro and in vivo evidence to support the
hypothesis that amyloid fibrils themselves, once deposited,
can act as niduses for propagation, thus enhancing amyloid
deposition.117–119
The signaling pathways activated when FLCs interact with
MCs are being defined.115,120 LCDD and AL amyloidosis
FLCs promote migration of c-fos and nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) to the
nucleus.115 The c-fos acts via platelet-derived growth factor-b
to promote cell surface ruffling, which further increases
interactions with FLCs, and also controls cell proliferation.115
LCDD FLCs promote more platelet-derived growth factor-b
release than amyloid FLCs; this may account for the early
proliferative lesions seen in LCDD, before matrix expansion
leads to cell deletion. NF-kB leads to gene activation and
release of monocyte chemotactic protein-1, which promotes
the recruitment of inflammatory cells.120,121
THE DIFFERENTIAL ROLE OF TRANSFORMING GROWTH
FACTOR-b IN AMYLOIDOSIS AND LCDD
Transforming growth factor (TGF)-b modulates progression
of LCDD and AL amyloidosis.122–124 In MC culture, LCDD
FLCs altered calcium homeostasis, reduced cell proliferation,
and increased ECM secretion including tenascin, an im-
portant protein component of ECM; these effects were
mediated by TGF-b.123,125,126 Blocking vesicular transport
between endoplasmic reticulum and the Golgi apparatus in
cells exposed to TGF-b normalized production of fibronectin
and tenascin.124 Platelet-derived growth factor-b and TGF-b
act independently; platelet-derived growth factor-b can
induce cell proliferation, but does not influence tenascin
and fibronectin production. TGF-b production is increased
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by LCDD FLCs, but not by AL amyloidosis FLCs.127 This may
explain why in LCDD there is greatly increased matrix,
whereas in amyloid, the matrix is replaced by fibrils. Finally,
cell apoptosis in glomerulosclerosis is, in part, triggered by
TGF-b, which may be important as glomerulosclerosis
becomes established in LCDD.122,128
MMPs
Glomerular pathology may reflect expression patterns of
MMPs.105,127 In one study, the expression of MMPs was six
times higher in the kidneys of patients with AL amyloidosis
compared with LCDD or negative controls.105 Furthermore,
MMP-2 activity is increased in AL amyloidosis compared
with LCDD.
Conversely, tenascin is present in excess in LCDD because
of decreased levels of MMP-7, which degrades the mole-
cule.70,97 There is inhibition of release of MMP-7 from MCs
by LCDD FLCs;129 this effect is not present with
AL amyloidosis FLCs and cast-nephropathy FLCs.127
Finally, ECM proteins may modulate MC function.130,131
Thus, abnormal mesangium produced by MCs activated by
FLCs may itself alter MC function and further potentiate
glomerulosclerosis.
TUBULOINTERSTITIAL DISEASE ASSOCIATED WITH LIGHT
CHAINS: PROXIMAL TUBULE
Light chain Fanconi syndrome
This is defined by selective proximal tubular reabsorptive
dysfunction, with glycosuria, aminoaciduria, phosphaturia,
and hyperuricosuria, as well as bicarbonate loss, causing a
type II renal tubular acidosis.132 PCD is the most common
underlying cause.133 The classical histological finding is
intralysosomal crystalline deposits of FLCs within PTECs.
There may be extrarenal crystal accumulation. FLCs of the
VkI subgroup are most frequently found,134,135 although
cases associated with l-FLCs have also been reported.136
FLCs derived from patients with this syndrome have
protease-resistant chain fragments, which may contribute to
the pathogenic features of the renal injury.137
In a sequence study of five k-FLCs from patients with light
chain Fanconi syndrome, all three FLCs associated with
crystalline deposits came from the same LCO2/O12 gene and
had non-polar AA residues exposed in the CDR1 region.138
Hydrophobic or non-polar AA residues have also been
reported elsewhere.135 Also, a patient with an incomplete
Fanconi syndrome and crystalline inclusions within PTECs
had a FLC of VkI subgroup, with non-polar residue
substitutions in CDR1.139 These abnormalities might cause
resistance to proteolysis, enhanced association, crystalliza-
tion, and interference with cell function.
In multiple myeloma, defects of tubular reabsorption and
urine acidification are usually a consequence of direct toxicity
of FLCs on PTECs in the absence of crystalline deposits.140
Myeloma FLCs can interfere with the uptake of alanine,
phosphate, and glucose.141,142 There has also been one report
of light chain Fanconi syndrome and nephrogenic diabetes
insipidus, suggesting that antidiuretic hormone resistance
can occur.143 Interestingly, this patient had distal (type I), not
proximal, renal tubular acidosis.
Cast nephropathy (myeloma kidney)
This is the most common renal manifestation in PCD.144,145
It is characterized by tubulointerstitial inflammation and
fibrosis, associated with hard, often fractured distal tubular
protein precipitates (casts), consisting of uromodulin
and FLC.146,147 There is usually a reaction around the
casts of multinucleated monocyte/macrophage-derived giant
cells.148,149 Cast formation may also be seen in up to a third
of cases of LCDD,95 but is rare in AL amyloidosis.
Proximal tubular toxicity
In PCD, exposure of PTECs to clonal FLCs can have a range
of pathological effects.38,150 These interactions are summar-
ized in Figure 2.
After clonal FLCs are bound by megalin and cubilin and
internalized by PTECs, the changes that occur range from
functional, such as suppression of Na–K–ATPase gene
expression and decreased cell metabolism,151 to ultrastruc-
tural, and from actin cytoskeleton abnormalities to DNA
degradation, apoptosis, and necrosis.152 FLCs may also
promote the phenotypic transformation of epithelial cells
to a myofibroblast phenotype by epithelial-to-mesenchymal
transition.153 This is associated with increased expression of
TGF-b-dependent ECM components.
Following endocytosis of clonal FLCs, nuclear transloca-
tion of NF-kB subunits lead to release of interleukin-6,
interleukin-8, and monocyte chemotactic protein-1;154 this
may explain much of the inflammation and fibrosis seen in
cast nephropathy. The signaling pathways activated by FLCs
that lead to the generation of these cytokines are being
elucidated. To date, linked roles have been identified for
mitogen-activated protein kinases (MAPKs), ERK 1/2, JNK
1/2, and p38,155 and pituitary adenylate cyclase-activating
polypeptide with 38 residues.156
Antibodies, through a reaction site localized to a highly
conserved segment of the light chain VL region, can oxidize
water to produce hydrogen peroxide (H2O2) and increase
target damage.157 In PTECs, intracellular H2O2 is generated
upon endocytosis of FLCs and oxidative stress ensues.158
H2O2 is an important intracellular second messenger,
159–161
and monocyte chemotactic protein-1 production was mark-
edly reduced on blocking H2O2 or NF-kB activity. Another
key signaling step in monocyte chemotactic protein-1 produc-
tion, consequent to H2O2, is the oxidation and activation of
c-Src, a redox-sensitive, non-receptor tyrosine kinase.162
The role of receptor-mediated endocytosis has been
established by showing that silencing megalin and cubilin
expression abrogated both cytokine production and epithe-
lial-to-mesenchymal transition.162,163 In these studies,
FLCs had far more powerful proinflammatory effects on
PTECs than other filtered proteins commonly implicated in
proximal tubule inflammation including albumin.38,153,154,158
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Although this effect may be multifactorial, it is likely
that a significant component is associated with H2O2
production.
DISTAL TUBULAR TOXICITY AND CAST FORMATION
When the pI of a protein is near the ambient pH, it carries no
net charge and may precipitate out of solution.164 There is
wide variation in pI of FLC clones, but this does not correlate
with cytotoxicity to PTECs,165–167 probably because receptor-
mediated uptake is pI independent. However, pI does
influence the site of precipitation in the nephron;165 there
is progressive acidification of tubular fluid, therefore the
lower the pI, the more distal the precipitation. Indeed,
alkalinization of urine ameliorated the negative effects of
FLCs on inulin clearance in rats.168 Other factors such as
tubular fluid concentration, reduced flow rates, and uromo-
dulin may also contribute.
Uromodulin is a heavily glycosylated 80-kDa protein
with a pI of 3.5, secreted by the thick ascending limb of the
loop of Henle.169–171 It is initially tethered to the luminal cell
surface membrane by a glycosylphosphatidylinositol anchor,
which is subsequently cleaved, allowing uromodulin to be
carried distally by tubular fluid.172,173 Uromodulin can self-
aggregate into a gel, facilitated by increasing electrolyte
concentrations.174–176 It binds to and coprecipitates with
many low-molecular weight proteins.165,177–179 Interactions
between FLCs and uromodulin are summarized in Figure 3.
Uromodulin also has a direct inflammatory effect,180–182 in
part through activation of immune/inflammatory cells.183–185
In macrophages and dendritic cells, this is via Toll-like
receptor-4 engagement and NF-kB mobilization.186,187
The mechanisms of cast formation have been elucidated in
detail; although some FLC clones have a direct effect on
PTECs, others precipitate in the distal tubule as casts.165 FLCs
bind to uromodulin to promote aggregation and cast
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border. Receptor-ligand complexes are concentrated in clathrin-coated pits (CCPs) and endocytosed to coated vesicles (CVs), which mature
into endosomal vesicles (EVs), where receptors and ligands are disengaged, following which receptors are recycled to the luminal cell
surface via dense apical tubules (DATs). FLCs undergo proteolysis into their constituent peptides and amino acids (AAs) within mature
lysosomes (Lys), and these products are returned to the circulation. Following endocytosis, an early event is the production of hydrogen
peroxide (H2O2). H2O2 oxidizes the tyrosine kinase c-Src to its active state. Downstream signaling leads to activation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB). Proteasome (Prot)-mediated degradation of the inhibitor of kB (IkB) permits nuclear
translocation of NF-kB subunits, leading to transcription of inflammatory cytokines. Recruitment of inflammatory cells to the interstitium
ensues, promoting fibrosis. Activation of mitogen-activated protein kinases (MAPKs) also occurs. These exert additional activating effects on
NF-kB as well as influencing transcription via other pathways. Epithelial-to-mesenchymal transition (EMT) is seen in vitro when PTECs are
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formation. This is both pI dependent and enhanced by
increasing sodium chloride and calcium concentrations.176
Cast precipitation in nephrons can occur down to very
low concentrations of FLC.188 There is a 9-AA sequence
on uromodulin that functions as a binding domain, inter-
acting with the CDR3 region of FLC.189–191 Influenced by
pH and other factors, FLCs in high concentrations may
also precipitate without interaction with uromodulin, and
be trapped within the uromodulin gel, forming part of a
larger cast.192 Cast formation causes intratubular obstruc-
tion with subsequent tubular atrophy.188 Another potential
factor in progressive renal injury in tubular obstruction
may be the upstream presence (as far as the glomerulus) of
uromodulin.193
In humans, acute kidney injury with cast nephropathy can
be precipitated by dehydration, hypercalcemia, administra-
tion of diuretics, non-steroidal anti-inflammatory agents,
and radiological contrast media.194 These observations are
consistent with studies that show enhanced binding of
FLCs to uromodulin by reducing extracellular fluid volumes,
the presence of acidic pH, increased calcium levels, and
increased sodium chloride in tubular fluid by administering
furosemide.188
CURRENT THERAPIES AND OUTLOOK FOR NOVEL THERAPIES
The treatment of any paraproteinaemic renal disease involves
targeting the underlying plasma cell clone with chemother-
apy, with or without stem-cell transplantation. This should
be in combination with supportive measures. Currently, there
are no established specific therapies for the renal component
of these diseases, but there are a number of exciting advances
that might improve patient outcomes.
In AL amyloidosis, treatments that enhance degradation
of deposits are being reported. In mice, a monoclonal
antibody directed against an amyloid-related FLC epitope
caused neutrophil infiltration and accelerated resolution of
deposits.195 Circulating serum amyloid protein levels may be
reduced by R-1-(6-(R-2-carboxy-pyrrolidin-1-yl)-6-oxo-hex-
anoyl)pyrrolidine-2-carboxylic acid (CPHPC), which pre-
vents binding of serum amyloid protein to amyloid
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proteins.196 Anti-serum amyloid protein antibodies instigate
giant cell-mediated, accelerated resolution of deposits in mice
and may be used in conjunction with CPHPC.197
In cast nephropathy, early reduction in FLCs can allow
renal recovery,198,199 but rapid progression of interstitial
fibrosis may occur.4 Early diagnosis and treatment is
therefore essential.200 There is uncontrolled evidence that
inclusion of bortezomib may add benefit, because of the fast
and deep chemotherapy response to the drug, and potential
direct inhibition of renal injury through NF-kB.201,202
Adjunctive extracorporeal FLC removal by protein-permeable
dialysis has yielded encouraging results.199 A randomized
controlled trial is under way.203 Future therapies are linked to
the potential to inhibit the interactions of FLCs with PTECs
and uromodulin. The pituitary immune-modulating peptide
pituitary adenylate cyclase-activating polypeptide with 38
residues effectively ameliorates the proinflammatory effects
of FLCs on PTECs and also suppresses myeloma cell growth.204
Additional potential therapeutic targets in PTECs include
H2O2, megalin and cubilin, and c-Src.
162 FLCs interact with
specific binding sites on uromodulin, highlighting this mole-
cule as another potential therapeutic target.191
CONCLUSION
All compartments of the kidney can be affected by
monoclonal FLCs. Knowledge of how injury is mediated is
growing. FLCs can promote functional changes; be processed
and deposited; mediate inflammation, apoptosis and fibrosis;
and physically obstruct nephrons. Each clone of FLC is
unique, and the precise type of pathology caused is
determined by the primary structure and posttranslational
modifications of that clone. Treatment of clonal FLC disease
is evolving and knowledge of the pathways that promote
renal injury should lead to further therapeutic developments.
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